Exelixis
EXEL
#1694
Rank
ยฃ8.95 B
Marketcap
ยฃ33.27
Share price
-0.02%
Change (1 day)
17.80%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): ยฃ1.78

According to Exelixis's latest financial reports the company's current EPS (TTM) is ยฃ1.79. In 2023 the company made an earnings per share (EPS) of ยฃ0.49 an increase over its 2022 EPS that were of ยฃ0.43.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)ยฃ1.78
2023ยฃ0.4914.61%
2022ยฃ0.43-22.97%
2021ยฃ0.56100%
2020ยฃ0.28-65.09%
2019ยฃ0.80-53.91%
2018ยฃ1.73333.96%
2017ยฃ0.40-260.61%
2016-ยฃ0.25-58.75%
2015-ยฃ0.60-42.45%
2014-ยฃ1.045.3%
2013-ยฃ0.99

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
GlaxoSmithKline
GSK
ยฃ2.70 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
ยฃ2.78 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
ยฃ5.70 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ2.23 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
ยฃ9.77 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
ยฃ7.83 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ1.29-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-ยฃ2.75-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-ยฃ0.63-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA